TLR3 and melanoma: Similarly, Neubert et al. showed that antigen targeting to cDC2s in the presence of anti-CD40 and Toll-like receptor 3 (TLR3) ligand resulted in the initiation of protective immunity against B16F10-OVA melanoma in both the prophylactic and therapeutic setting [56].